Kwong, Louis M <br/><br/>
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.  [electronic resource] 

 -  The American journal of managed care  Feb 2011 
 - S22-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1936-2692 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anticoagulants--economics<br/>Arthroplasty, Replacement, Hip--adverse effects<br/>Arthroplasty, Replacement, Knee--adverse effects<br/>Cost-Benefit Analysis<br/>Enoxaparin--economics<br/>Factor Xa Inhibitors<br/>Humans<br/>Morpholines--economics<br/>Rivaroxaban<br/>Thiophenes--economics<br/>United States<br/>Venous Thromboembolism--economics